Friday, 13 Sep 2019

You are here

Rituximab Effects on ANCA, IgG and Infectious Risk in ANCA-Associated Vasculitis

Rituximab has significantly changed the management of patiehts with ANCA-associated vasculitis (AAV). Yet the longitudinal assessment of such patients needs to be guideded by clinical and laboratory parameters.

A multicenter, retrospective study assessed the effect of rituximab on autoantibodies and immunoglobulin levels, and clinical outcomes in 239 AAV patients.

During RTX induction phase (n=53 patients), there was a decline in IgG levels (6% per month) and ANCA levels (47%) - this included a similar fall in anti-MPO and anti-PR3 titers.

During RTX maintenance treatment (over a median 2.4 yrs), a decline in IgG levels (0.6% per year) was seen. Significant hypogammaglobulinemia (IgG < 400 mg/dL) occurred in 4.6% of patients. Serious infections during maintenance occurred at a rate of 8.5 [95% CI, 0.66 to 1.1] per 100 patient years and were independently associated with an IgG level < 400mg/dL. (Analyses of the RA cohort has shown that hypo-IgG is a risk factor for serious infection).

B cell targeted therapy with RTX does results in a decline in ANCA titers as well as total IgG levels in a minority of patients (4.6%) who may be at risk for serious infections. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Riociguat Fails in Systemic Sclerosis-Associated Digital Ulcers

Riociguat is an oral, selective soluble guanylate cyclase stimulator that has been studied in patients with digital ulcers (DU) due to systemic sclerosis (SSc) but study results show that short term (16 weeks) riociquat therapy does not sufficiently reduce the DU burden in SSc patients.

Nintedanib FDA Approved for Scleroderma Lung Disease

Last Friday, the US Food and Drug Administration approved Ofev (nintedanib) to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. ILD as a complication of SSc may lead to progressive loss of lung function and may be associated with a significant mortality risk. Prior to the approval of Olev, there were no FDA approved drugs for SSc-ILD.

With Autoimmunity, Checkpoint Inhibitors Can Be Used

Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.

New EULAR/ACR Classification Criteria for SLE

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) have jointly developed new classification criteria for systemic lupus erythematosus (SLE); prompted by the need for criteria that were both highly sensitive and specific. The net result is improved sensitivity and specificity, but the use of positive ANA requirement along with a longer list of weighted criteria ensures its utility in SLE research (including early or latent SLE), but not clinical practice.

Sjogren's Syndrome at Risk for Psychiatric Disorders

A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS).